DURECT CORPORATION (DRRX) Stock Fundamental Analysis

NASDAQ:DRRX • US2666055007

1.91 USD
-0.02 (-1.04%)
At close: Sep 10, 2025
1.94 USD
+0.03 (+1.57%)
After Hours: 9/10/2025, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Overall DRRX gets a fundamental rating of 2 out of 10. We evaluated DRRX against 192 industry peers in the Pharmaceuticals industry. While DRRX seems to be doing ok healthwise, there are quite some concerns on its profitability. DRRX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year DRRX has reported negative net income.
  • DRRX had a negative operating cash flow in the past year.
  • In the past 5 years DRRX always reported negative net income.
  • In the past 5 years DRRX always reported negative operating cash flow.
DRRX Yearly Net Income VS EBIT VS OCF VS FCFDRRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M -20M -30M

1.2 Ratios

  • With a Return On Assets value of -27.86%, DRRX perfoms like the industry average, outperforming 54.31% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of -99.86%, DRRX is in line with its industry, outperforming 41.62% of the companies in the same industry.
Industry RankSector Rank
ROA -27.86%
ROE -99.86%
ROIC N/A
ROA(3y)-55.09%
ROA(5y)-41.09%
ROE(3y)-139.78%
ROE(5y)-96.71%
ROIC(3y)N/A
ROIC(5y)N/A
DRRX Yearly ROA, ROE, ROICDRRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

  • Looking at the Gross Margin, with a value of 62.60%, DRRX is in the better half of the industry, outperforming 70.56% of the companies in the same industry.
  • In the last couple of years the Gross Margin of DRRX has remained more or less at the same level.
  • DRRX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 62.6%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.8%
GM growth 5Y0.25%
DRRX Yearly Profit, Operating, Gross MarginsDRRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • DRRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, DRRX has more shares outstanding
  • Compared to 5 years ago, DRRX has more shares outstanding
  • There is no outstanding debt for DRRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
DRRX Yearly Shares OutstandingDRRX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
DRRX Yearly Total Debt VS Total AssetsDRRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

  • DRRX has an Altman-Z score of -67.96. This is a bad value and indicates that DRRX is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of -67.96, DRRX is not doing good in the industry: 92.39% of the companies in the same industry are doing better.
  • DRRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -67.96
ROIC/WACCN/A
WACC10.88%
DRRX Yearly LT Debt VS Equity VS FCFDRRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

  • A Current Ratio of 0.98 indicates that DRRX may have some problems paying its short term obligations.
  • DRRX's Current ratio of 0.98 is on the low side compared to the rest of the industry. DRRX is outperformed by 80.71% of its industry peers.
  • A Quick Ratio of 0.95 indicates that DRRX may have some problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 0.95, DRRX is doing worse than 74.62% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.98
Quick Ratio 0.95
DRRX Yearly Current Assets VS Current LiabilitesDRRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 83.61% over the past year.
  • DRRX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -62.89%.
  • DRRX shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -39.51% yearly.
EPS 1Y (TTM)83.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.67%
Revenue 1Y (TTM)-62.89%
Revenue growth 3Y-47.43%
Revenue growth 5Y-39.51%
Sales Q2Q%-79.41%

3.2 Future

  • Based on estimates for the next years, DRRX will show a very strong growth in Earnings Per Share. The EPS will grow by 60.95% on average per year.
  • DRRX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 53.91% yearly.
EPS Next Y-105.89%
EPS Next 2Y-24.45%
EPS Next 3Y57.26%
EPS Next 5Y60.95%
Revenue Next Year-92.31%
Revenue Next 2Y-22.88%
Revenue Next 3Y45.1%
Revenue Next 5Y53.91%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
DRRX Yearly Revenue VS EstimatesDRRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
DRRX Yearly EPS VS EstimatesDRRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4 6 8

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for DRRX. In the last year negative earnings were reported.
  • Also next year DRRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DRRX Price Earnings VS Forward Price EarningsDRRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DRRX Per share dataDRRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 -0.2 -0.3 -0.4

4.3 Compensation for Growth

  • DRRX's earnings are expected to grow with 57.26% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-24.45%
EPS Next 3Y57.26%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • DRRX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

DURECT CORPORATION

NASDAQ:DRRX (9/10/2025, 8:00:01 PM)

After market: 1.94 +0.03 (+1.57%)

1.91

-0.02 (-1.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-12
Earnings (Next)11-11
Inst Owners22.34%
Inst Owner Change-100%
Ins Owners11.82%
Ins Owner Change-1.35%
Market Cap59.31M
Revenue(TTM)3.12M
Net Income(TTM)-3.48M
Analysts45.71
Price Target2.55 (33.51%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)16.78%
Min EPS beat(2)-9.24%
Max EPS beat(2)42.81%
EPS beat(4)3
Avg EPS beat(4)391.47%
Min EPS beat(4)-9.24%
Max EPS beat(4)1511.48%
EPS beat(8)6
Avg EPS beat(8)215.39%
EPS beat(12)10
Avg EPS beat(12)147.91%
EPS beat(16)13
Avg EPS beat(16)114.43%
Revenue beat(2)2
Avg Revenue beat(2)24.63%
Min Revenue beat(2)7.9%
Max Revenue beat(2)41.37%
Revenue beat(4)2
Avg Revenue beat(4)-9.47%
Min Revenue beat(4)-82.8%
Max Revenue beat(4)41.37%
Revenue beat(8)3
Avg Revenue beat(8)-13.96%
Revenue beat(12)3
Avg Revenue beat(12)-15.73%
Revenue beat(16)5
Avg Revenue beat(16)-0.21%
PT rev (1m)0%
PT rev (3m)-50%
EPS NQ rev (1m)0%
EPS NQ rev (3m)5.43%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)50%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 19.01
P/FCF N/A
P/OCF N/A
P/B 17.03
P/tB 78.24
EV/EBITDA N/A
EPS(TTM)-0.1
EYN/A
EPS(NY)-0.42
Fwd EYN/A
FCF(TTM)-0.45
FCFYN/A
OCF(TTM)-0.45
OCFYN/A
SpS0.1
BVpS0.11
TBVpS0.02
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -27.86%
ROE -99.86%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 62.6%
FCFM N/A
ROA(3y)-55.09%
ROA(5y)-41.09%
ROE(3y)-139.78%
ROE(5y)-96.71%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.8%
GM growth 5Y0.25%
F-Score3
Asset Turnover0.25
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 5.65%
Cap/Sales 0.22%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.98
Quick Ratio 0.95
Altman-Z -67.96
F-Score3
WACC10.88%
ROIC/WACCN/A
Cap/Depr(3y)86.47%
Cap/Depr(5y)78.99%
Cap/Sales(3y)0.86%
Cap/Sales(5y)0.93%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)83.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.67%
EPS Next Y-105.89%
EPS Next 2Y-24.45%
EPS Next 3Y57.26%
EPS Next 5Y60.95%
Revenue 1Y (TTM)-62.89%
Revenue growth 3Y-47.43%
Revenue growth 5Y-39.51%
Sales Q2Q%-79.41%
Revenue Next Year-92.31%
Revenue Next 2Y-22.88%
Revenue Next 3Y45.1%
Revenue Next 5Y53.91%
EBIT growth 1Y32.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-229.17%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y52.4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y52.28%
OCF growth 3YN/A
OCF growth 5YN/A

DURECT CORPORATION / DRRX FAQ

What is the ChartMill fundamental rating of DURECT CORPORATION (DRRX) stock?

ChartMill assigns a fundamental rating of 2 / 10 to DRRX.


What is the valuation status for DRRX stock?

ChartMill assigns a valuation rating of 1 / 10 to DURECT CORPORATION (DRRX). This can be considered as Overvalued.


How profitable is DURECT CORPORATION (DRRX) stock?

DURECT CORPORATION (DRRX) has a profitability rating of 1 / 10.


What is the financial health of DURECT CORPORATION (DRRX) stock?

The financial health rating of DURECT CORPORATION (DRRX) is 4 / 10.